The role of the CpG island methylator phenotype on survival outcome in colon cancer

Gut and Liver

Volumn 9, Issue 2, 2015, Pages 202-207

  Kang, Ki Joo ^a   Min, Byung Hoon ^b   Ryu, Kyung Ju ^b   Kim, Kyoung Mee ^b   Chang, Dong Kyung ^b   Kim, Jae J ^b   Rhee, Jong Chul ^b   Kim, Young Ho ^b  

^a Hallym University College of Medicine   (China)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Colonic neoplasms; CpG island methylator phenotype; Survival outcome

Indexed keywords

CACNA1G PROTEIN; INSULIN GROWTH FACTOR 2; NEUROGENIN 1; SOMATOMEDIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSCRIPTION FACTOR RUNX3; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COLON CANCER; CPG ISLAND; CPG ISLAND METHYLATOR PHENOTYPE; DISEASE FREE SURVIVAL; DNA EXTRACTION; DNA METHYLATION; FEMALE; HUMAN; KOREAN (PEOPLE); LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; OUTCOME ASSESSMENT; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; AGE; COLORECTAL TUMOR; GENETICS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PHYSIOLOGY; PROGNOSIS; SEX DIFFERENCE; SOUTH KOREA; SURVIVAL ANALYSIS;

ADULT; AGE FACTORS; AGED; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; FEMALE; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PHENOTYPE; PROGNOSIS; REPUBLIC OF KOREA; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 84923698905     PISSN: 19762283     EISSN: 20051212     Source Type: Journal    
DOI: 10.5009/gnl13352     Document Type: Article

References (30)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009;361:2449-2460.
3. Kim YS, Deng G. Epigenetic changes (aberrant DNA methylation) in colorectal neoplasia. Gut Liver 2007;1:1-11.
4. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999;96:8681-8686.
5. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004;4:988-993.
6. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65:6063-6069.
7. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006;38:787-793.
8. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007;50:113-130.
9. Rashid A, Issa JP. CpG island methylation in gastroenterologic neoplasia: a maturing field. Gastroenterology 2004;127:1578-1588.
10. Hawkins N, Norrie M, Cheong K, et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 2002;122:1376-1387.
11. van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, Iacopetta B. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 2002;51:797-802.
12. Samowitz WS, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005;129:837-845.
13. Issa JP, Shen L, Toyota M. CIMP, at last. Gastroenterology 2005;129:1121-1124.
14. Kim JH, Shin SH, Kwon HJ, Cho NY, Kang GH. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch 2009;455:485-494.
15. Lee S, Cho NY, Choi M, Yoo EJ, Kim JH, Kang GH. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol Int 2008;58:104-113.
16. Dahlin AM, Palmqvist R, Henriksson ML, et al. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res 2010;16:1845-1855.
17. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-96.
18. Oh SW, Kim YH, Choi YS, et al. The comparison of the risk factors and clinical manifestations of proximal and distal colorectal cancer. Dis Colon Rectum 2008;51:56-61.
19. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag, 2002.
20. Ogino S, Kawasaki T, Brahmandam M, et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006;8:209-217.
21. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-5257.
22. Loukola A, Eklin K, Laiho P, et al. Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC). Cancer Res 2001;61:4545-4549.
23. Hoang JM, Cottu PH, Thuille B, Salmon RJ, Thomas G, Hamelin R. BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res 1997;57:300-303.
24. Issa JP. Methylation and prognosis: of molecular clocks and hypermethylator phenotypes. Clin Cancer Res 2003;9:2879-2881.
25. Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 2003;9:2898-2903.
26. Ogino S, Meyerhardt JA, Kawasaki T, et al. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch 2007;450:529-537.
27. Shen L, Catalano PJ, Benson AB 3rd, O'Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res 2007;13:6093-6098.
28. Bae JM, Kim JH, Cho NY, Kim TY, Kang GH. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. Br J Cancer 2013;109:1004-1012.
29. Oh SY, Lee JM, Lee HW, et al. Clinicopathological significance of microsatellite instability in sporadic colorectal cancer. J Korean Surg Soc 2006;71:420-425.
30. Kang KJ, Sinn DH, Park SH, et al. Adenoma incidence after resection of sporadic colorectal cancer with microsatellite instability. J Surg Oncol 2010;101:577-581.